Related Experiment Videos
Designer antibacterial peptides kill fluoroquinolone-resistant clinical isolates
Laszlo Otvos1, John D Wade, Feng Lin
1OLPE, LLC, 801 Mockingbird Lane, Audubon, Pennsylvania 19403, USA. lotvos@comcast.net
Journal of Medicinal Chemistry
|August 5, 2005
Summary
New proline-rich antibacterial peptides show promise against fluoroquinolone-resistant bacteria like E. coli and K. pneumoniae. These peptides are effective and less toxic, offering a potential new treatment for urinary tract infections.
Area of Science:
- Microbiology
- Biochemistry
- Pharmacology
Background:
- Fluoroquinolone resistance in *Escherichia coli* and *Klebsiella pneumoniae* is a growing concern for urinary tract infections (UTIs).
- Conventional peptide antibiotics often suffer from toxicity or limited efficacy.
- There is a critical need for novel antimicrobial agents to combat resistant bacterial strains.
Purpose of the Study:
- To design and develop novel proline-rich antibacterial peptides with enhanced bacterial cell entry and low eukaryotic toxicity.
- To evaluate the in vitro efficacy of these peptides against fluoroquinolone-resistant pathogens.
- To assess the potential of these peptides as therapeutic agents for UTIs.
Main Methods:
- Utilized multiple sequence alignment and optimization to design multifunctional proline-rich peptides.
- Assessed bacterial cell entry, DnaK-binding ability, and eukaryotic toxicity.
- Determined minimal inhibitory concentrations (MICs) in Muller-Hinton broth against clinical pathogens.
- Evaluated peptide activity in the presence of mouse serum and compared potency to ciprofloxacin against resistant isolates.
Main Results:
- Designed peptides that effectively entered bacterial cells while maintaining low toxicity.
- Achieved minimal inhibitory concentrations (MICs) ranging from 8-32 µg/mL against various clinical pathogens.
- The lead peptide (compound 5, A3-APO) demonstrated full activity in mouse serum.
- Peptide 5 was four times more potent than ciprofloxacin against eight fluoroquinolone-resistant clinical isolates.
Conclusions:
- Novel proline-rich peptides demonstrate significant antibacterial activity against fluoroquinolone-resistant *E. coli* and *K. pneumoniae*.
- Compound 5 (A3-APO) shows promising in vitro efficacy, low toxicity, and stability in serum, suggesting therapeutic potential.
- The findings support the development of these peptides as a viable alternative for treating complex UTIs.